Company news

MoonLake Immunotherapeutics news in 2026

MoonLake Immunotherapeutics's news releases, calls and decks from 2026, newest first.

View company

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

November 4, 2026

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

August 10, 2026

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

June 23, 2026

MoonLake Immunotherapeutics Announces Proposed Public Offering

June 22, 2026

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

June 21, 2026

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

May 9, 2026

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

March 27, 2026

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

February 21, 2026

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

February 10, 2026

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

February 1, 2026

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

January 7, 2026

Decks in 2026